JP2015511226A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511226A5 JP2015511226A5 JP2014554975A JP2014554975A JP2015511226A5 JP 2015511226 A5 JP2015511226 A5 JP 2015511226A5 JP 2014554975 A JP2014554975 A JP 2014554975A JP 2014554975 A JP2014554975 A JP 2014554975A JP 2015511226 A5 JP2015511226 A5 JP 2015511226A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- sample
- level
- patient
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593249P | 2012-01-31 | 2012-01-31 | |
| US61/593,249 | 2012-01-31 | ||
| PCT/US2013/023921 WO2013116385A1 (en) | 2012-01-31 | 2013-01-30 | Predictive biomarker for hypoxia-activated prodrug therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017214327A Division JP2018052956A (ja) | 2012-01-31 | 2017-11-07 | 低酸素活性化プロドラッグ療法のための予測バイオマーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015511226A JP2015511226A (ja) | 2015-04-16 |
| JP2015511226A5 true JP2015511226A5 (https=) | 2016-03-17 |
Family
ID=48905801
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014554975A Pending JP2015511226A (ja) | 2012-01-31 | 2013-01-30 | 低酸素活性化プロドラッグ療法のための予測バイオマーカー |
| JP2017214327A Withdrawn JP2018052956A (ja) | 2012-01-31 | 2017-11-07 | 低酸素活性化プロドラッグ療法のための予測バイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017214327A Withdrawn JP2018052956A (ja) | 2012-01-31 | 2017-11-07 | 低酸素活性化プロドラッグ療法のための予測バイオマーカー |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20150005264A1 (https=) |
| EP (1) | EP2810076A4 (https=) |
| JP (2) | JP2015511226A (https=) |
| WO (1) | WO2013116385A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1896040B1 (en) | 2005-06-29 | 2012-08-01 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
| EP2793882A4 (en) | 2011-12-22 | 2015-04-29 | Threshold Pharmaceuticals Inc | ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER |
| WO2015025283A2 (en) * | 2013-08-20 | 2015-02-26 | Stichting Maastricht Radiation Oncology "Maastro-Clinic" | Dual action carbonic anhydrase inhibitors |
| WO2015069489A1 (en) * | 2013-11-06 | 2015-05-14 | Merck Patent Gmbh | Predictive biomarker for hypoxia-activated prodrug therapy |
| US10760130B2 (en) | 2014-11-19 | 2020-09-01 | Molecular Templates, Inc. | Predictive biomarker for hypoxia-activated prodrug therapy |
| US20210369746A1 (en) * | 2016-08-01 | 2021-12-02 | Molecular Templates, Inc. | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer |
| WO2023025312A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 使用th-302治疗parp抑制剂耐药的患者 |
| CN117651548B (zh) | 2021-08-27 | 2026-03-03 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
| US20250186468A1 (en) | 2022-03-15 | 2025-06-12 | Ascentawits Pharmaceuticals, Ltd. | Method for treating patient with brca-mutated cancer |
| CN119384281A (zh) | 2022-04-15 | 2025-01-28 | 深圳艾欣达伟医药科技有限公司 | 使用th-302单药或联用parp抑制剂治疗癌症的方法 |
| CN119233822A (zh) | 2022-05-23 | 2024-12-31 | 深圳艾欣达伟医药科技有限公司 | 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法 |
| CN119894521A (zh) | 2022-09-22 | 2025-04-25 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| KR20250160163A (ko) | 2023-02-27 | 2025-11-11 | 아센타위츠 파마슈티컬즈 리미티드 | 용액, 동결건조 제형, 동결건조 제형 단위 패키지, 주사제, 및 주사제 제조 방법 |
| WO2025026214A1 (zh) | 2023-07-28 | 2025-02-06 | 深圳艾欣达伟医药科技有限公司 | 治疗p53基因突变或缺陷阴性癌症、肿瘤患者 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE026218T2 (en) * | 2002-02-21 | 2016-05-30 | Inst Virology | MN / CA IX-Specific Monoclonal Antibodies and Methods for MN / CA IX Deficient Mice |
| EP1743038A4 (en) * | 2004-05-04 | 2007-11-21 | Bayer Healthcare | MN / CA IX / CA9 AND KIDNEY CANCER PROGNOSIS |
| ES2877629T3 (es) * | 2010-07-12 | 2021-11-17 | Immunogenesis Inc | Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer |
-
2013
- 2013-01-30 JP JP2014554975A patent/JP2015511226A/ja active Pending
- 2013-01-30 WO PCT/US2013/023921 patent/WO2013116385A1/en not_active Ceased
- 2013-01-30 EP EP13744373.5A patent/EP2810076A4/en not_active Withdrawn
- 2013-01-30 US US14/375,417 patent/US20150005264A1/en not_active Abandoned
-
2017
- 2017-11-07 JP JP2017214327A patent/JP2018052956A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015511226A5 (https=) | ||
| Ko et al. | Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling | |
| Saad et al. | ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer | |
| Wu et al. | Heat shock proteins and cancer | |
| Li et al. | Uncontrolled inflammation induced by AEG-1 promotes gastric cancer and poor prognosis | |
| Chen et al. | Angiopoietin‐like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma | |
| Singh et al. | Single agent and synergistic activity of the “first-in-class” dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma | |
| JP2016513640A5 (https=) | ||
| Mittal et al. | Recent advances in targeted therapy for glioblastoma | |
| Spiegelberg et al. | The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells | |
| JP2018503618A5 (https=) | ||
| Schmidt et al. | Targeting protein synthesis in colorectal cancer | |
| EA201290712A1 (ru) | Альфа-излучающие комплексы | |
| TR201909355T4 (tr) | Oral uygulama için proton bağlayıcı polimerler. | |
| Zhu et al. | REGγ drives Lgr5+ stem cells to potentiate radiation induced intestinal regeneration | |
| Thomas et al. | Advancing therapeutics in small-cell lung cancer | |
| JP2019537619A5 (https=) | ||
| Chen et al. | Resveratrol, a novel inhibitor of fatty acid binding protein 5, inhibits cervical cancer metastasis by suppressing fatty acid transport into nucleus and downstream pathways | |
| Miller et al. | Differential involvement of gp130 signalling pathways in modulating tobacco carcinogen-induced lung tumourigenesis | |
| Cañadas et al. | Angiopoietin-2 is a negative prognostic marker in small cell lung cancer | |
| Martin-Liberal et al. | Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours | |
| JP2018537519A5 (https=) | ||
| Woodcock et al. | A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424 | |
| Boonkaew et al. | Extracellular vesicles in metabolic dysfunction-associated steatotic liver disease: From intercellular signaling to clinical translation | |
| Huang et al. | Somatostatin octapeptide inhibits cell invasion and metastasis in hepatocellular carcinoma through PEBP1 |